N-terminal proBNP: A novel biomarker for the diagnosis, risk stratification and management of congestive heart failure

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 3, 2005, Pages 487-496

  O'Donoghue, Michelle ^a   Januzzi Jr , James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Brain natriuretic peptide; Congestive heart failure; Diagnostic resting; Natriuretic peptides; NT proBNP

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NESIRITIDE; SPIRONOLACTONE; VASODILATOR AGENT;

ADJUVANT THERAPY; AMINO TERMINAL SEQUENCE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; HEALTH CARE ACCESS; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HORMONE SYNTHESIS; HOSPITALIZATION; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; NONHUMAN; PREDICTION; PREVALENCE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK ASSESSMENT;

EID: 18844435222     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.3.487     Document Type: Review

References (86)

1. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice. The case of heart failure. Arch. Intern. Med. 159, 1690-1700 (1999).
2. Funk M, Krumholz HM. Epidemiologic and economic impact of advanced heart failure. J. Cardiovasc. Nurs. 10(2), 1-10 (1996).
3. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991).
4. CIBIS II investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 353, 9-13 (1999).
5. RALES investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol. 78, 902-907 (1996).
6. Henry JP, Gauer OH, Reeves JL. Evidence of the atrial location of receptors influencing urine flow. Circ. Res. 4, 85-90 (1956).
7. Kisch B. Electromicroscopy of the atrium of the heart. Exp. Med. Surg. 14, 99-112 (1956).
8. Kisch B. A significant electron microscopic difference between the atria and ventricles of the mammalian heart. Exp. Med. Surg. 21, 193-221 (1963).
9. Jamieson JD, Palade GE. Specific granules in atrial muscle cells. J. Cell. Biol. 23, 151-172 (1964).
10. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28, 89-94 (1981).
11. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 332, 78-81(1988).
12. Tsutamoto T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96, 509-516 (1997).
13. Maeda K, Takayoshi T, Wada A et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am. Heart J. 135, 825-832 (1998).
14. Dao Q, Krishnaswamy P, Kazanegra R et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll. Cardiol. 37, 379-385 (2001).
15. McCullough PA, Nowak RM, McCord J et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not property (BNP) multinational study. Circulation 106, 416-422 (2002).
16. Chen V Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J. Am. Coll. Cardiol. 37, 386-391 (2001).
17. Yasue H, Yoshimura M, Sumida H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90(1), 195-203 (1994).
18. Richards AM, Crozier IG, Yandle TG et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br. Heart J. 69, 414-417 (1993).
19. Magga J, Vuolteenaho O, Tokola H et al. B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann. Med. 30(Suppl. 1), 39-45 (1998).
20. Magga J, Marttila M, Mntymaa P. Vuolteenaho O, Ruskoaho H. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats. Endocrinology 134, 2505-2515 (1994).
21. Tsurada T, Boerrigter G, Huntley BK et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ. Res. 91, 1127-1134 (2002).
22. Richards AM, McDonald D, Fitzpatrick MA et al. Atrial natriuretic hormone has biological effects in man at physiological plasma concentrations. J. Clin. Endocrinol. Metab. 67, 1134-1139 (1988).
23. Kone BC. Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc. Res. 51, 429-441 (2001).
24. Luchner A, Stevens TL, Borgeson DD et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am. J. Physiol. 274, H1684-H1689 (1998).
25. Hystad ME, Geiran OR, Attramadal H et al. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol. Scand. 171, 395-403 (2001).
26. Harada M, Saito Y, Kuwahara K et al. Interaction of myocytes and non-myocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. J. Cardiovasc. Pharmacol. 31(Suppl. 1), S357-S359 (1998).
27. Hunt PJ, Richards AM, Nicholls MG et al. Immunoreactive amino-terminal probrain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin. Endocrinol. (Oxford) 47, 287-296 (1997).
28. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J. Lab. Clin. Med. 134, 437-444 (1999).
29. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev. Cardiovasc. Med. 4, 72-80 (2003).
30. Raymond I, Groenning BA, Hildebrandt PR et al. The influence of age, sex and other variables on the plasma level of N-terminal probrain natriuretic peptide in a large sample of the general population. Heart 89, 745-751(2003).
31. Redfield MM, Rodenheffer RJ, Jacobsen SJ et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol. 40, 976-982 (2002).
32. McCullough PA, Duc P, Omland T et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am. J. Kidney Dis. 41, 571-579 (2003).
33. Tsutamoto T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure; prognostic role of plasma brain natriuretic peptide concentrations in patients with chronic symptomatic left ventricular dysfunction. Circulation 96, 509-516 (1997).
34. Lee SC, Stevens TL, Sanberg SM et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the out-patient treatment of heart failure. J. Card. Fail. 8, 149-154 (2002).
35. Koglin J, Pehlivanli S, Schwaiblmair M et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J. Am. Coll. Cardiol. 38, 1934-1941 (2001).
36. Omland T, Aakvaag A, Bonarjee VVS et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93, 1963-1969 (1996).
37. Clerico A, Iervasi G, Del Chicca MG et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J. Endocrinol. Invest. 21, 170-179 (1998).
38. Pfeffer MA, Braunwald E, Moy LA, Basta L, Brown EJ, SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N. Engl. J. Med. 327, 669-677 (1992).
39. Bay M, Kirk V, Parner J et al. NT-proBNP: a new diagnostic screening tool to differentiate patients with a normal and reduced systolic function. Heart. 89, 150 (2003).
40. Talwar S, Squire IB, Davies JE et al. Plamsa N-terminal probrain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high-risk poplulation. Eur. J. Heart Failure 20, 1736-1744 (1999).
41. Hobbs FDR, Davis RC, Roalfe AK et al. Reliability of N-terminal probrain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high-risk community populations. Br. Med. J. 324, 1498 (2002).
42. Groenning BA, Raymond I, Hildebrandt et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal probrain natriuretic peptide concentrations in a large sample of the general population. Heart 90, 297-303 (2004).
43. McDonagh TA, Holmer S, Raymond I et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur. J. Heart Failure 6, 269-273 (2004).
44. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347, 161-167 (2002).
45. Morrison LK, Harrison A, Krishnaswamy P et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J. Am. Coll. Cardiol. 39, 202-209 (2002).
46. Dao Q, Krishnaswamy P, Kazanegra R et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll. Cardiol. 37, 379-385 (2001).
47. Davis M, Espiner E, Richards G et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 343, 440-444 (1994).
48. Cabanes L, Richaud-Thiriez B, Fulla Y et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 120, 2047-2050 (2001).
49. Lainchbury JG, Campbell E, Frampton CM et al. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J. Am. Coll. Cardiol. 42, 728-735 (2003).
50. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur. J. Heart Failure 6, 301 (2004).
51. Januzzi JL, Camargo CA, Anwaruddin S et al. The N-terminal proBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am. J. Cardiol. 95, 948-954 (2005).
52. Baggish A, Siebert U, Lainchbury J et al. A validated clinical and biochemical diagnostic score for the diagnosis of acute CHF: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute CHF Score. Am. Heart J. (2005) (In Press).
53. Siebert U, Januzzi JL, Beinfield MT, Cameron R, Gazelle GS. Cost-effectiveness of using NT-proBNP to guide the diagnostic assessment and management of dyspneic patients in the Emergency Department. Submitted (2004).
54. Dauterman KW, Massie BM, Gheorghiade M. Heart failure with preserved systolic function: a common and costly clinical entity. Am. Heart J. 135(Suppl.), S310-S319 (1998).
55. Vasan RS, Larson MG, Benjamin FJ et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J. Am. Coll. Cardiol. 33, 1948-1955 (1999).
56. Senni M, Tribouilloy CM, Rodeheffer RJ et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 98, 2282-2289 (1998).
57. Hammerer-Lercher A, Ludwig W, Falkensammer G et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin. Chem. 50, 1174-1183 (2004).
58. Maisel AS, McCord J, Nowak RM et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly (BNP) multinational study. J. Am. Coll. Cardiol. 41, 2010-2017 (2003).
59. O'Donoghue M, Chen A, Baggish AL et al. The effects of ejection fraction on N-terminal proBNP and BNP levels among patients with acute CHF: analysis from the PRIDE Study. J. Cardiac Fail. (2005) (In Press).
60. Wright SP, Doughty RN, Pearl A et al. Plasma amino-terminal probrain natriuretic peptide and accuracy of heart failure diagnosis in primary care. J. Am. Coll. Cardiol. 42, 1793-1800 (2003).
61. McCullough PA, Philbin EF, Spertus JA et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) Study. J. Am. Coll. Cardiol. 39, 60 (2002).
62. Gustafsson F, Torp-Pedersen C, Brendorp B et al. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur. Heart J. 24, 863-870 (2003).
63. Richards AM, Doughty R, Nicholls MG et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 99, 786-792 (1999).
64. Richards AM, Doughty R, Nicholls MG et al. Plasma N-terminal probrain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J. Am. Coll. Cardiol. 37(7), 1781-1787 (2001).
65. Kirk V, Bay M, Parner J, Krogsgaard K et al. N-terminal proBNP and mortality in hospitalized patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur. J. Heart Fail. 6, 335-341 (2004).
66. Gardner RS, Ozalp F, Murday AJ et al. N-terminal probrain natriuretic peptide in patients with advanced heart failure. Eur. Heart J. 24, 1735 (2003).
67. Hartmann F, Packer M, Coats AJ et al. Prognostic impact of plasma N-terminal probrain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial. Circulation 110, 1780-1786 (2004).
68. Gardner RS, Ozalp F, Murday AJ et al. N-terminal probrain natriuretic peptide in patients with advanced heart failure. Eur. Heart J. 24, 1735 (2003).
69. Publication Committee for the VMAC investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287, 1531-1540 (2002).
70. Latini R, Masson S, Anand I et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106, 2454-2458 (2002).
71. Yasumura Y, Miyatake K, Okamoto H et al. Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II-receptor blocker therapy in heart failure. Circ. J. 68, 361-366 (2004).
72. Conway DG, Sullivan R, McCullough PA. Improved symptoms, physical limitation, and self-efficacy after resynchronization in a patient with heart failure and a prolonged QRS duration. Rev. Cardiovasc. Med. 5, 53-57 (2004).
73. Rademaker MT, Charles CJ, Espiner EA et al. Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. Clin. Sci. (London) 106, 569-576 (2004).
74. Troughton RW, Framptom CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126 (2000).
75. Bettencourt P, Azevedo A, Pimenta J et al. N-terminal probrain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110, 2168-2174 (2004).
76. Bettencourt P, Ferreira S, Azevedo A, Ferreira A. Preliminary data on the potential usefulness of B-type natriuretic peptide in predicting outcome after hospital discharge in patients with heart failure. Am. J. Med. 113, 215-219 (2002).
77. FRISC-2 investigators. Invasive compared with noninvasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet 354, 708-715 (1999).
78. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of an early invasive and conservative strategies in patients with unstable coronary syndromes treated with Iib/IIIa inhibitor tirofiban. N. Engl. J. Med. 344, 1879-1887 (2001).
79. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal probrain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J. Am. Coll. Cardiol. 40, 437 (2002).
80. James SK, Lindahl B, Siegbahn A et al. N-terminal probrain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: GUSTO IV substudy. Circulation 108, 275 (2003).
81. Jernberg T, Lindahl B, Siegbahn A et al. N-terminal probrain natriuretic peptide in relation to inflammation, myocardiac necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J. Am. Coll. Cardiol. 42, 1909-1916 (2003).
82. Omland T, Aakvaag A, Bonarjee W et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93, 1963-1969 (1996).
83. Richards AM, Nicholls MG, Yandle T et al. Plasma N-terminal probrain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97, 1921-1929 (1998).
84. Omland T, Persson A, Ng L et al. N-terminal proB-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106, 2913-2918 (2002).
85. Kucher N, Printzen G, Doernhoefer T et al. Low probrain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 107, 1576-1578 (2003).
86. Palladini G, Campana C, Klersy C et al. Serum N-terminal probrain natriuretic peptide is a sensitive marker of myocardial dysftinction in AL amyloidosis. Circulation 107, 2440-24445 (2003).